ITRA20130015A1 - COMPOUND AIMED AT IMPROVING BREATHING - Google Patents
COMPOUND AIMED AT IMPROVING BREATHINGInfo
- Publication number
- ITRA20130015A1 ITRA20130015A1 IT000015A ITRA20130015A ITRA20130015A1 IT RA20130015 A1 ITRA20130015 A1 IT RA20130015A1 IT 000015 A IT000015 A IT 000015A IT RA20130015 A ITRA20130015 A IT RA20130015A IT RA20130015 A1 ITRA20130015 A1 IT RA20130015A1
- Authority
- IT
- Italy
- Prior art keywords
- balsamic
- compound according
- blend
- oil
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 13
- 230000029058 respiratory gaseous exchange Effects 0.000 title claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 7
- 241001479543 Mentha x piperita Species 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 4
- 239000001771 mentha piperita Substances 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 244000166124 Eucalyptus globulus Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 241000721662 Juniperus Species 0.000 claims description 2
- 241001012590 Juniperus communis subsp. communis Species 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 23
- 150000003839 salts Chemical class 0.000 description 8
- 239000013078 crystal Substances 0.000 description 4
- 235000019568 aromas Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000019994 cava Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
"COMPOSTO FINALIZZATO AL MIGLIORAMENTO DELLA "COMPOUND AIMED AT THE IMPROVEMENT OF
RESPIRAZIONE. " BREATHING. "
DESCRIZIONE DESCRIPTION
La presente invenzione à ̈ relativa ad un composto finalizzato al miglioramento della respirazione. The present invention relates to a compound aimed at improving respiration.
Il composto in oggetto à ̈, in particolare, costituito da cristalli di Sodio cloruro (NaCl) puro, di tipo alimentare, di origine minerale o anche marina, addizionati con miscela balsamica di oli essenziali. Le deficienze respiratorie che si riscontrano al giorno d'oggi, peraltro in notevole aumento, sono causate in prevalenza da tabagismo, inquinamento dell'aria, allergie acquisite e congenite, malattie professionali. La scienza medica dà un contributo fondamentale per la diagnosi e la cura di tali patologie nelle persone colpite. The compound in question is, in particular, made up of pure sodium chloride (NaCl) crystals, of food type, of mineral or even marine origin, added with a balsamic blend of essential oils. The respiratory deficiencies that are found nowadays, however on a considerable increase, are mainly caused by smoking, air pollution, acquired and congenital allergies, occupational diseases. Medical science makes a fundamental contribution to the diagnosis and treatment of these diseases in those affected.
In affiancamento alle cure indispensabili sono stati creati, presso cliniche, terme e centri benessere, dei luoghi specifici definiti "grotte del sale", per la respirazione dell'aria salina da tempo riconosciuta benefica. Alongside the indispensable treatments, specific places called "salt caves" have been created in clinics, spas and wellness centers, for breathing in the saline air which has long been recognized as beneficial.
All'affermarsi della respirazione salina quale coadiuvante terapico ha molto contribuito l'sistenza di grandi centri assistiti sorti da molto tempo nelle grotte sotterranee scavate nel salgemma per l'estrazione dello stesso. The existence of large assisted centers which have arisen for a long time in the underground caves dug into the rock salt for its extraction has greatly contributed to the affirmation of saline respiration as a therapeutic adjuvant.
Questi centri si trovano in Germania, in Polonia e in altri paesi, e lì il paziente sosta durante il giorno per determinati periodi consigliati. These centers are located in Germany, Poland and other countries, and the patient stays there during the day for certain recommended periods.
Quanto descritto à ̈, in sostanza, lo stato attuale della tecnica della coadiuvazione naturale a base salina atta a migliorare la respirazione. What has been described is, in essence, the current state of the technique of natural salt-based aid to improve breathing.
Premesso questo, l'idea inventiva in oggetto à ̈ maturata per agevolare 1'utilizzatore nella reperibilità di un prodotto facilmente disponibile a breve distanza, riducendo il tempo e i costi di uno spostamento forzato. Having said this, the inventive idea in question was developed to facilitate the user in the availability of a product easily available at a short distance, reducing the time and costs of a forced movement.
Il preparato, in funzione della sua formulazione, mostra efficacia per la sinergia benefica sviluppata durante l'inspirazione dell'aria salina con gli aromi derivanti dagli oli essenziali balsamici Menta piperita, Eucalipto, Ginepro (Miscela balsamica), o anche solo Menta piperita Eucalipto, sostanze queste indicate allo scopo e riconosciute dalla letteratura scientifica riferita alle piante medicinali. The preparation, according to its formulation, shows efficacy for the beneficial synergy developed during the inhalation of saline air with the aromas deriving from the balsamic essential oils Peppermint, Eucalyptus, Juniper (Balsamic blend), or even just Peppermint Eucalyptus, these substances indicated for the purpose and recognized by the scientific literature referring to medicinal plants.
In sintesi, i microgranuli salini inspirati con gli oli balsamici aromatici agiscono positivamente aumentando la funzionalità degli alveoli bronchiali, favorendo una capacità respiratoria maggiore con azione lievemente batteriostatica. In summary, the saline microgranules inspired with the aromatic balsamic oils act positively by increasing the functionality of the bronchial alveoli, favoring a greater respiratory capacity with a slightly bacteriostatic action.
Sono scientificamente riconosciute l'azione batteriostatica del sale e l'azione antiinfiammatoria degli oli essenziali sopracitati. Una riflessione non di secondaria importanza riguarda i componenti, i quali non sono molecole sintetiche ma naturali. The bacteriostatic action of salt and the anti-inflammatory action of the aforementioned essential oils are scientifically recognized. A reflection not of secondary importance concerns the components, which are not synthetic but natural molecules.
L'inspirazione può avvenire con un apposito strumento di dimensioni anche tascabili che, una volta caricato del sale , consente il passaggio dell'aria attraverso il prodotto con effetto dì trascinamento dell'aria salina balsamica. Inoltre il prodotto può anche essere utilizzato in soluzione acquosa vaporizzata. The inhalation can take place with a special instrument, even pocket-sized, which, once loaded with salt, allows the passage of air through the product with the effect of entrainment of the balsamic saline air. Furthermore, the product can also be used in a vaporized aqueous solution.
I componenti del prodotto finito sono i seguenti: 1) SODIO CLORURO puro Food Grade (NaCl), di origine minerale, definito anche salgemma o sale di roccia, o anche di orìgine marina, senza additivi o coadiuvanti all'origine, a cristalli traslucidi. Titolo 99% minimo - Granulometria: 10-15% > 3,5 mm, 75-80% da 1 a 3,5 mm, 7-10% < 1 mm. The components of the finished product are as follows: 1) SODIUM CHLORIDE pure Food Grade (NaCl), of mineral origin, also defined as rock salt or rock salt, or even sea salt, without additives or adjuvants at the origin, in crystals translucent. 99% minimum titre - Granulometry: 10-15%> 3.5 mm, 75-80% from 1 to 3.5 mm, 7-10% <1 mm.
La diversificazione granulometrica dei cristalli salini à ̈ essenziale per formare le vie preferenziali del passaggio dell'aria di respirazione, che trascina microgranuli volatili e aromi balsamici; The granulometric diversification of the salt crystals is essential to form the preferential ways for the passage of the breathing air, which carries volatile microgranules and balsamic aromas;
2) Miscela balsamica Food grade costituita da: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10% o anche Mentha piperita oil 40-70% Eucalyptus globulus oil 30- 2) Food grade balsamic blend consisting of: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10% or even Mentha piperita oil 40-70% Eucalyptus globulus oil 30-
La concentrazione della Miscela balsamica sul prodotto finito à ̈ compresa nell'intervallo tra 50 e 500 ppm, concentrazioni queste adeguate a conferire efficacia al prodotto finito. The concentration of the balsamic blend on the finished product is between 50 and 500 ppm, these concentrations are adequate to give efficacy to the finished product.
Tale Miscela balsamica e il prodotto finito non sono soggetti a contaminazione batterica, non contengono antiossidanti e conservanti, sono esenti da OGM, non contengono sostanze classificate CMR di categoria 1,2 o 3 (informazione basata sulla direttiva 2003/15/CE e 63/548/CE per le sostanze carcinogene, mutagene o tossiche) , non sono venuti a contatto in produzione con derivati di origine animale, non sono stati trattati con radiazioni ionizzanti, sono esenti da solventi residui, contaminanti, metalli pesanti, ftalati e glicoli. This balsamic blend and the finished product are not subject to bacterial contamination, do not contain antioxidants and preservatives, are free from GMOs, do not contain substances classified as CMR category 1,2 or 3 (information based on directive 2003/15 / EC and 63 / 548 / EC for carcinogenic, mutagenic or toxic substances), have not come into contact in production with derivatives of animal origin, have not been treated with ionizing radiation, are free from residual solvents, contaminants, heavy metals, phthalates and glycols.
Il procedimento di preparazione del composto in oggetto à ̈ il seguente. The preparation procedure of the compound in question is as follows.
In un particolare mescolatore in acciaio inox a rotazione decentrata si pone il sale da aromatizzare con la Miscela balsamica, la quale à ̈ aggiunta in tre parti, in tre momenti della miscelazione. The salt to be flavored with the balsamic blend is placed in a particular stainless steel mixer with decentralized rotation, which is added in three parts, in three stages of mixing.
Il prodotto finito à ̈ scaricato dal mescolatore e versato nella tramoggia di una inflaconatrice per la formazione, chiusura e relativa etichettatura dei flaconi. The finished product is discharged from the mixer and poured into the hopper of a bottle filling machine for the formation, closure and relative labeling of the bottles.
I flaconi confezionati sono finalizzati a ricostituire la carica di prodotto fresco, in sostituzione di quello esaurito, in una "pipa " di aspirazione con contenitore microforato alla base. The packaged bottles are designed to reconstitute the charge of fresh product, to replace the exhausted one, in a suction "pipe" with a micro-perforated container at the base.
Lo scuotimento del contenitore prima di ogni ciclo di aspirazione consente così di modificare la posizione dei cristalli di sale e quindi delle vie preferenziali di aspirazione, il rinnovo della superficie salina di contatto, la produzione di nuovi microcristalli. The shaking of the container before each aspiration cycle thus allows to modify the position of the salt crystals and therefore of the preferential aspiration routes, the renewal of the saline contact surface, the production of new microcrystals.
La "pipa" à ̈ dotata nella parte superiore di un piano anch'esso microforato per il passaggio dell'aria e il trattenimento del sale non conforme alla respirazione. La decadenza del prodotto à ̈ constatabile dall'esaurimento degli aromi, dopo 30/60 giorni dall'apertura del flacone, in funzione dell'intensità d'uso del prodotto stesso. The "pipe" is equipped in the upper part with a micro-perforated surface for the passage of air and the retention of salt that does not conform to breathing. The decadence of the product is ascertained from the exhaustion of the aromas, after 30/60 days from the opening of the bottle, depending on the intensity of use of the product itself.
La preparazione della Miscela balsamica à ̈ definita da una distinta base precostituita, che ne indica la quantità complessiva da impiegare e le relative percentuali e quantità dei componenti, in base alla quantità totale di prodotto determinata dalla commessa Per agevolare e consentire una razionale diffusione della Miscela balsamica aromatizzante nella massa salina si diluisce la stessa con l'aggiunta, in rapporto 1:10, di alcool etilico puro. The preparation of the balsamic blend is defined by a pre-established bill of materials, which indicates the overall quantity to be used and the relative percentages and quantities of the components, based on the total quantity of product determined by the order To facilitate and allow a rational diffusion of the Blend balsamic flavoring in the saline mass is diluted with the addition, in a ratio of 1:10, of pure ethyl alcohol.
La presenza di alcool etilico puro, anche se in minime quantità , favorisce la bio-stabilità della massa durante la lavorazione non aumentando il grado di umidità del prodotto finito; infatti l'alcool svanisce per evaporazione durante il processo di lavorazione e confezionamento senza lasciare residui. The presence of pure ethyl alcohol, even if in minimal quantities, favors the bio-stability of the mass during processing by not increasing the degree of humidity of the finished product; in fact the alcohol vanishes by evaporation during the manufacturing and packaging process without leaving residues.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000015A ITRA20130015A1 (en) | 2013-06-12 | 2013-06-12 | COMPOUND AIMED AT IMPROVING BREATHING |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000015A ITRA20130015A1 (en) | 2013-06-12 | 2013-06-12 | COMPOUND AIMED AT IMPROVING BREATHING |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITRA20130015A1 true ITRA20130015A1 (en) | 2014-12-13 |
Family
ID=49035811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000015A ITRA20130015A1 (en) | 2013-06-12 | 2013-06-12 | COMPOUND AIMED AT IMPROVING BREATHING |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITRA20130015A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225394A1 (en) * | 2002-06-04 | 2003-12-04 | Peter Ahnblad | Pharmaceutical composition and nasal rinsing device therefor |
| WO2005053638A2 (en) * | 2003-11-29 | 2005-06-16 | Passion For Life Healthcare Limited | Composition and delivery system |
| US20060019987A1 (en) * | 2004-07-23 | 2006-01-26 | Fust Charles A | Methods and compositions for inhibiting, destroying, and/or inactivating viruses |
| EP2528591A2 (en) * | 2010-01-29 | 2012-12-05 | Mahmut Bilgic | Effervescent formulations comprising cefaclor |
| DE202013000748U1 (en) * | 2013-01-24 | 2013-02-19 | Merz Pharma Gmbh & Co. Kgaa | Sprayable liquid preparation for especially nasal application with increased local residence time |
| EP2574333A1 (en) * | 2011-09-27 | 2013-04-03 | Friulchem SpA | N-acetylcysteine effervescent tablet and its therapeutical applications |
-
2013
- 2013-06-12 IT IT000015A patent/ITRA20130015A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225394A1 (en) * | 2002-06-04 | 2003-12-04 | Peter Ahnblad | Pharmaceutical composition and nasal rinsing device therefor |
| WO2005053638A2 (en) * | 2003-11-29 | 2005-06-16 | Passion For Life Healthcare Limited | Composition and delivery system |
| US20060019987A1 (en) * | 2004-07-23 | 2006-01-26 | Fust Charles A | Methods and compositions for inhibiting, destroying, and/or inactivating viruses |
| EP2528591A2 (en) * | 2010-01-29 | 2012-12-05 | Mahmut Bilgic | Effervescent formulations comprising cefaclor |
| EP2574333A1 (en) * | 2011-09-27 | 2013-04-03 | Friulchem SpA | N-acetylcysteine effervescent tablet and its therapeutical applications |
| DE202013000748U1 (en) * | 2013-01-24 | 2013-02-19 | Merz Pharma Gmbh & Co. Kgaa | Sprayable liquid preparation for especially nasal application with increased local residence time |
Non-Patent Citations (2)
| Title |
|---|
| "SinoFresh Antiseptic Nasal Spray for Sinus Infection Symptoms", 29 May 2005 (2005-05-29), XP002714387, Retrieved from the Internet <URL:www.sinofresh.com/FAQ_SCIENCE.php> [retrieved on 20131008] * |
| MARK SANDERS: "Inhalation therapy: an historical review", PRIMARY CARE RESPIRATORY JOURNAL, vol. 16, no. 2, 1 April 2007 (2007-04-01), pages 71, XP055083133, ISSN: 1471-4418, DOI: 10.3132/pcrj.2007.00017 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180522A1 (en) | ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT | |
| CO2017012766A2 (en) | Orodispersible dosing unit containing an estetrol component | |
| Sahoo et al. | Aphrodisiac activity of polyherbal formulation in experimental models on male rats | |
| CL2011001178A1 (en) | Use of (r) -7-chloro-niquinuclidin-3-1l) senzo [b] thiophene-2-carboxamide or a salt thereof or a pharmaceutical composition comprising it to prepare a useful medication to improve cognition in a patient suffering from Alzheimer's or schizophrenia. | |
| BR112015027017A2 (en) | inhalable pharmaceutical compositions and inhaler devices containing the same | |
| BR112014029735A2 (en) | dosage form and formulation of abediterol | |
| JP2018027989A (en) | Pharmaceutical composition containing loxoprofen or salt thereof (4) | |
| ECSP055821A (en) | NEW PULVERULENT FORMULATION CONTAINING INHALATION TIOTROPY | |
| ITRA20130015A1 (en) | COMPOUND AIMED AT IMPROVING BREATHING | |
| JP2013027383A (en) | Oral food producing negative hydrogen ion after eating | |
| BR112015020019A2 (en) | tablet for the treatment of sore throat, hoarseness and associated dry cough and inflammatory diseases of the oral and pharyngeal cavity | |
| BR112017018569A2 (en) | stable formulation for parenteral administration of tapentadol | |
| BR112014004339A2 (en) | oral suspension | |
| EA201592297A1 (en) | AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS | |
| JP6087826B2 (en) | Pharmaceutical composition containing loxoprofen or a salt thereof | |
| Shamkuwar et al. | Antidiarrhoeal activity of an ayurvedic formulation: Enterocin | |
| PH12014501837A1 (en) | Use of modafinil in the treatment of cocaine addicts | |
| Hamila et al. | Urinary Mercury level, neurobehavioral performance and some biochemical markers in children with amalgam restorations | |
| CN106580941B (en) | A kind of powder and preparation method thereof of gargling containing sodium azulenesulfonate | |
| Timbuak et al. | Acute hepatotoxicity and nephrotoxicity study of orally administered aqueous and ethanolic extracts of Carica papaya seeds in adult Wistar rats | |
| Bugailiškis | Šiaulių miesto bibliotekos ir jų raida | |
| BR112021011125A2 (en) | Oral pharmaceutical composition with a plant alkaloid for addiction treatment | |
| CN102749244A (en) | Tissue transparent reagent, and preparation method and applications thereof | |
| HRP20231108T1 (en) | A pharmaceutical composition for enhancing iron levels in blood, comprising iron (iii) polymaltose and another active substance, suitable for iron absorption, selected from calcium folinate pentahydrate, vitamin c or a combination of both | |
| ITMI20101426A1 (en) | COMPOSITION CONTAINING CONDROITIN SULFATE |